Navigation Links
ATS Medical Announces FDA Clearance and First Implant of New ATS Simulus Semi-Rigid Annuloplasty Band
Date:7/6/2009

MINNEAPOLIS, July 6 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced FDA clearance and the first implant of the ATS Simulus(R) Semi-Rigid Annuloplasty Band. The Simulus Semi-Rigid Annuloplasty Band was developed through the Company's collaboration with Genesee BioMedical and represents the latest addition to the expanding portfolio of valve repair products.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

Annuloplasty rings and bands are used in those cases where repair of a patient's heart valve is preferable to replacement of the valve. This new repair product has clinical applications that expand the existing therapeutic options for surgeons and their patients. The Simulus Semi-Rigid Band is specifically designed to respect the natural motion of the mitral annulus during the cardiac cycle allowing for a more physiologic valve repair. This unique characteristic can be particularly important in patients where both the aortic and mitral valves are being treated.

Dr. Robert F. Hebeler, Jr., who performed the first implant of the ATS Simulus Semi-Rigid Band at Heart Hospital Baylor in Plano, Texas commented, "This Simulus Semi-Rigid Band represents the next advancement in annuloplasty repair rings and provides an excellent option for my patients with mitral valve regurgitation. The band retains the natural saddle shape of the mitral valve annulus and preserves mobility during the cardiac phases, particularly in the aorto-mitral junction. These design characteristics make the Simulus Semi-Rigid Band easy to implant."

Michael Dale, President and CEO of ATS Medical added, "We are excited about the growth and innovation we have brought to the annuloplasty repair market. Our portfolio of Simulus annuloplasty products continues to be an important contribution to our heart valve therapy product platform."

About ATS Medical

ATS Medical, Inc. is dedicated to "Advancing The Standards" of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2008 and its most recent quarterly report on Form 10-Q.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GoldenAgeMedical.Com Announces National TV Campaign
2. NEJM study addresses impact of Medicare Part D on medical spending
3. Scienceroll.com on the Medical Implications of Virtual Worlds
4. Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules
5. American Society of Medical Doctors Established to Protect the Bond Between Physicians and Patients; Organizing Doctors to Oppose Government-Run Health Care
6. Successful Beginning for Wellstone Muscular Dystrophy Center at Boston Biomedical Research Institute
7. Winner Medical Signs PurCotton Sales Agreement With Consumer Products Leader in China
8. Omega Medical Solutions Selects Allscripts Practice Management and Allscripts Payerpath Revenue Cycle Management
9. Cord Blood Awareness Month: Understanding Still Low, Despite Medical Advancements
10. Materials and Processes for Medical Devices Event Brings Clinicians, Engineers, Designers Together
11. Nation Takes a Big Step Toward Learning Which Medical Treatments Work Best, a Major Advance in Fixing Our Broken Health-Care System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
Breaking Medicine Technology: